CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company’s commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcar...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
CareDx, Inc announced delayed 10-Q filing
Aug 16 16
On 08/16/2016, CareDx, Inc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Caredx, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Year 2016
Aug 10 16
CareDx Inc. reported Unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported total revenue of $10,708,000 against $7,129,000 a year ago. Loss from operations was $6,849,000 against $2,886,000 a year ago. Loss before income taxes was $10,728,000 against $3,185,000 a year ago. Net loss attributable to the company was $10,335 against $3,185,000 a year ago. Net loss per basic and diluted share attributable to the company was $0.76 against $0.27 a year ago. Non-GAAP net loss was $3,945,000 against $2,632,000 a year ago. Non-GAAP basic and diluted net loss per share attributable the company was $0.29 against $0.22 a year ago. The increase in the year-over-year net loss reflects acquisition costs, acquisition related amortization of intangible assets, purchase accounting adjustments, a charge for a change in the estimated fair value of warrants, and investment in the development of AlloSure. The increase in the year-over-year non-GAAP net loss primarily reflects its investment in the development of AlloSure.
For the six months, the company reported total revenue of $17,270,000 against $14,344,000 a year ago. Loss from operations was $13,418,000 against $4,277,000 a year ago. Loss before income taxes was $20,433,000 against $5,457,000 a year ago. Net loss attributable to the company was $20,087,000 against $5,457,000 a year ago. Net loss per basic and diluted share attributable to the company was $1.57 against $0.46 a year ago. Non-GAAP net loss was $8,326,000 against $4,876,000 a year ago. Non-GAAP basic and diluted net loss per share attributable the company was $0.64 against $0.41 a year ago.
For the full year 2016, the company reiterates revenue guidance. The company expects fiscal 2016 revenue to grow by low- to mid-single digits on a pro forma basis over fiscal 2015 revenue, assuming that the Allenex acquisition closed on January 1, 2016. Actual reported results will only include Allenex results subsequent to the close of the acquisition on April 14, 2016, and the company expects reported revenue for the full year 2016 to be in the range of $40 million to $42 million.
CareDx, Inc to Report Q2, 2016 Results on Aug 10, 2016
Aug 1 16
CareDx, Inc announced that they will report Q2, 2016 results at 5:00 PM, Eastern Standard Time on Aug 10, 2016